Value of p16 expression in the triage of liquid-based cervical cytology with atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions

Chinese Medical Journal

Volumn 124, Issue 16, 2011, Pages 2443-2447

  Ma, Yuan Ying ^a   Cheng, Xiao Dong ^b   Zhou, Cai Yun ^b   Qiu, Li Qian ^a   Chen, Xiao Duan ^a   Lü, Wei Guo ^a   Xie, Xing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Zhejiang University School of Medicine   (China)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Cytology; Human papillomavirus; P16 ink4a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 80051980155     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.16.008     Document Type: Article

References (31)

1. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 2003; 127: 946-949.
2. ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188: 1393-1400.
3. zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999; 111: 581-587.
4. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papilloma-virus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26 Suppl 10: K29-K41.
5. Franco E. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003; 31: 89-96.
6. Lorincz A, Richart R. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127: 959-968.
7. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Eng J Med 1998; 338: 423-428.
8. Dehn D, Torkko KC, Shroyer KR. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 2007; 111: 1-14.
9. Horn LC, Reichert A, Oster A, Arndal SF, Trunk MJ, Ridder R, et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2008; 32: 502-512.
10. Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 937-945.
11. Davies P, Kornegay J, Iftner T. Current methods of testing for human papillomavirus. Best Pract Res Clin Obstet Gynaecol 2001; 15: 677-700.
12. Tavassoli FA, Devilee P. WHO Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2000: 269-270.
13. Wang SS, Trunk M, Schiffman M, Herrero R, Sherman ME, Burk RD, et al. Validation of P16 as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 1355-1360.
14. Wentzensen N, Bergeron C, Cas F, Eschenbach D, Vinokurova S, von Knebel Doeberitz M. Evaluation of a nuclear score for P16a-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005; 105: 461-467.
15. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11: 201-222.
16. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 280-293.
17. Solomon D, Schiffman M, Tarone R; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 293-299.
18. ALTS group. Human papilloma virus testing for triage of Women with cytologic evidence for low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000; 92: 397-402.
19. Li Y, Ye F, Lu WG, Zeng WJ, Wei LH, Xie X. Detection of hTERC in Cervical Cancer and Precancerous Lesions, Comparison with Cytologic and HPV DNA Test. Int J Gynecol Cancer 2010; 20: 631-637.
20. Murphy N, Ring M, Killalea AG, Uhlmann V, O'Donovan M, Mulcahy F, et al. P16 as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003; 56: 56-63.
21. zur Hausen H, Papillomaviruses and cancer: from basic studies to clinical application, Nat Rev Cancer 2002; 2: 342-350.
22. Mihara K, Cao X, Yen A, Chandler S, Driscoll B, Murphree AL, et al. Cell cycle dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 1989; 246: 1300-1303.
23. Zeng WJ, Li Y, Fei HL, Cheng XD, Ye F, Lii WG, et al. The value of p16ink4a expression by fluorescence in situ hybridization in triage for high risk HPV positive in cervical cancer screening. Gynecol Oncol 2011; 120: 84-88.
24. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, et al. P16 immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis. Cancer Treatment Reviews 2009; 35: 210-220.
25. Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 2007; 111: 58-66.
26. Trunk MJ, Dallenbach-Hellweg G, Ridder R, Petry KU, Ikenberg H, Schneider V, et al. Morphologic characteristics of p16INK4a positive cells in cervical cytology samples. Acta Cytol 2004; 48: 771-782.
27. Hu L, Guo M, He Z, Thornton J, McDaniel LS, Hughson MD. Human papillomavirus genotyping and P16 expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol 2005; 18: 267-273.
28. Mao C, Balasubramanian A, Yu M, Kiviat N, Ridder R, Reichert A, et al. Evaluation of a new P16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer 2007; 120: 2435-2438.
29. Duncan L, Jacob S, Hubbard E. Evaluation of P16 as a diagnostic tool in the triage of Pap smears demonstrating atypical squamous cells of undetermined significance. Cancer 2008; 114: 34-48.
30. Negri G, Vittadello F, Romano F, Kasal A, Rivasi F, Girlando S, et al. P16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004; 445: 616-620.
31. Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T. Usefulness of liquid-based cytology specimens for the immunocytochemical study of P16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer 2004; 102: 100-108.